aTYR PHARMA INC Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
aTYR PHARMA INC (ATYR) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-05
- aTYR PHARMA INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00.
- aTYR PHARMA INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- aTYR PHARMA INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- aTYR PHARMA INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- aTYR PHARMA INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00.
- aTYR PHARMA INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- aTYR PHARMA INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $1.85M, a 78.68% decline from fiscal 2022.
- aTYR PHARMA INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $8.70M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-05 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $0.00 10-K · filed 2026-03-05 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | -$120.00K derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | -$120.00K derived: sum of 3 quarters · filed 2026-03-05 | -$84.00K derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-02 | -$120.00K derived: sum of 2 quarters · filed 2026-03-05 | -$84.00K derived: sum of 3 quarters · filed 2026-03-05 | $811.00K derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | -$120.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$84.00K derived: sum of 2 quarters · filed 2026-03-05 | $811.00K derived: sum of 3 quarters · filed 2026-03-05 | $1.85M 10-K · filed 2026-03-05 |
| 2023-09-30 | $36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $931.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.97M 10-Q · filed 2024-11-07 | $9.87M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $895.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.94M 10-Q · filed 2024-08-13 | $9.83M derived: sum of 3 quarters · filed 2025-03-13 | $10.27M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $1.04M 10-Q · filed 2024-05-02 | $8.94M derived: sum of 2 quarters · filed 2025-03-13 | $9.37M derived: sum of 3 quarters · filed 2025-03-13 | $9.74M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $7.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $8.33M derived: sum of 2 quarters · filed 2025-03-13 | $8.70M derived: sum of 3 quarters · filed 2025-03-13 | $8.70M 10-K · filed 2025-03-13 |
| 2022-09-30 | $432.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $800.00K derived: sum of 2 quarters · filed 2023-11-09 | $800.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $368.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $368.00K 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-14 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |